Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-03-13
2008-12-16
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S007100, C530S388220, C530S387100
Reexamination Certificate
active
07465449
ABSTRACT:
Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5019368 (1991-05-01), Epstein et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6291650 (2001-09-01), Winter et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6303313 (2001-10-01), Wigler et al.
patent: 6307026 (2001-10-01), King et al.
patent: 6358710 (2002-03-01), Graves et al.
patent: 6692741 (2004-02-01), Huang et al.
patent: 2001/0056076 (2001-12-01), Huang et al.
patent: 239400 (1987-09-01), None
patent: 0719859 (1996-07-01), None
patent: 843961 (1998-05-01), None
patent: 90/07861 (1990-07-01), None
patent: 99/07405 (1999-02-01), None
patent: WO 99/37683 (1999-07-01), None
Huang et al. The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci. Aug. 1998;111 ( Pt 15):2189-95.
Mitijans et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci. Aug. 1995;108 ( Pt 8):2825-38.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Weinreb et al. Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem. Apr. 23, 2004;279(17):17875-87.
Wu et al.Stepwise in vitro affinity maturation of Vitaxin, an avb3-specific humanized mAb. Proc. Natl. Acad. Sci. USA vol. 95, pp. 6037-6042, May 1998.
Munger et al. A Mechanism for Regulating Pulmonary Inflammation and Fibrosis: The Integrin vβ6 Binds and Activates Latent TGF β1. Cell, vol. 96, Issue 3, Feb. 5, 1999, pp. 319-328.
Ludbrook et al. The integrin avb3 is a receptor for the latency-associated peptides of transforming growth factors b1 and b3. Biochem. J. (2003) 369 (311-318).
Sheppard et al., J. Biol. Chem., 265(20):11502-11507 (1990).
Pittet et al., J. Clin. Invest., 107(12):1537-1544 (2001).
Franko et al., Radiat. Res., 140(3):347-355 (1994).
Cosgrove et al., Am. J. Pathol., 157(5):1649-1659 (2000).
Ziyadeh et al., Proc. Natl. Acad. Sci. USA, 97(14):8015-8020 (2000).
Ma, LJ. et al., Lab Investigation, 81:189A (2001).
Ma, LJ. et al., J. Am. Soc. Nephrol., 12:819A (2001).
Oft et al., Curr. Biol., 8(23):1243-1252 (1998).
Akhurst et al., Trends Cell Biol., 11(11):S44-S51 (2001).
Huang et al., J. Cell Biol., 133(4):921-928 (1996).
Huang et al., Am. J. Respir. Cell Mol. Biol., 13(2):245-251 (1995).
Abe et al., Anal. Biochem., 216(2):276-284 (1994).
Huang et al., J. Cell Sci., 111(Pt 15):2189-2195 (1998).
Thomas et al., J. Invest. Dermatol., 117(1):67-73 (2001).
Brunton et al., Neoplasia, 3(3):215-226 (2001).
Agrez et al., Int. J. Cancer, 81(1):90-97 (1999).
Breuss et al., J. Cell Sci., 108(Pt 6):2241-2251 (1995).
Ma et al., Kidney Int., 53(4):937-944 (1998).
George et al., Proc. Natl. Acad. Sci. USA, 96(22):12719-12724 (1999).
George et al., Am. J. Pathol., 156(1):115-124 (2000).
Kunicki et al., J. Biol. Chem., 272(7):4103-4107 (1997).
Kunichi et al., J. Biol. Chem., 270(28):16660-16665 (1995).
Munger et al., Cell, 96(3):319-328 (1999).
Weinreb et al., J. Biol. Chem., 279(17):17875-17887 (2004).
Sheppard, Physiol. Rev., 83(3):673-686 (2003).
Knight et al., Am. J. Pathol., 161(3):771-779 (2002).
Sheppard, Chest, 120(1 Suppl):49S-53S (2001).
Kaminski et al., Proc. Natl. Acad. Sci. USA, 97(4):1778-1783 (2000).
Huang et al., Am. J. Respir. Cell Mol. Biol., 19(4):636-642 (1998).
Sheppard, Am. J. Respir. Cell Mol. Biol., 19(3):349-351 (1998).
Dixit et al., J. Biol. Chem., 271(42):25976-25980 (1996).
Weinacker et al., J. Biol. Chem., 269(9):6940-6948 (1994).
Agrez et al., J. Cell Biol., 127(2):547-556 (1994).
Busk et al., J. Biol. Chem., 267(9):5790-5796 (1992).
Leone Diane R.
Sheppard Dean
Simon Kenneth J.
Violette Shelia M.
Weinreb Paul H.
Biogen Idec MA Inc.
Haddad Maher M
McAndrews Held & Malloy Ltd.
The Regents of the University of California
LandOfFree
Anti-α v β 6 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-α v β 6 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-α v β 6 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034087